Collectively these data suggest that analysis of MRD is confounded by underlying disease risk, higher-risk subgroups are unlikely to achieve an MRD- state, and that specific subgroups such as NPM1 and IDH mutated AML may benefit the most from MRD-directed treatment. This evidence concerns the gene NPM1 and acute myeloid leukemia.